1411 related articles for article (PubMed ID: 19376495)
21. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
22. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
[TBL] [Abstract][Full Text] [Related]
23. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
Gupta B; Adewoyin T; Patel SK; Sivaprasad S
Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
[TBL] [Abstract][Full Text] [Related]
24. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
[TBL] [Abstract][Full Text] [Related]
25. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
[TBL] [Abstract][Full Text] [Related]
26. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.
Querques G; Azrya S; Martinelli D; Berboucha E; Feldman A; Pece A; Coscas G; Soubrane G; Souied EH
Br J Ophthalmol; 2010 Mar; 94(3):292-6. PubMed ID: 19951942
[TBL] [Abstract][Full Text] [Related]
27. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
28. Ranibizumab for refractory uveitis-related macular edema.
Acharya NR; Hong KC; Lee SM
Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
Rosenfeld PJ; Shapiro H; Tuomi L; Webster M; Elledge J; Blodi B;
Ophthalmology; 2011 Mar; 118(3):523-30. PubMed ID: 20920825
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
31. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
Theodossiadis PG; Liarakos VS; Sfikakis PP; Vergados IA; Theodossiadis GP
Am J Ophthalmol; 2009 May; 147(5):825-30, 830.e1. PubMed ID: 19211094
[TBL] [Abstract][Full Text] [Related]
34. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration.
Bhatnagar P; Spaide RF; Takahashi BS; Peragallo JH; Freund KB; Klancnik JM; Cooney MJ; Slakter JS; Sorenson JA; Yannuzzi LA
Retina; 2007 Sep; 27(7):846-50. PubMed ID: 17891007
[TBL] [Abstract][Full Text] [Related]
35. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
[TBL] [Abstract][Full Text] [Related]
36. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
Mantel I; Zografos L; Ambresin A
Ophthalmologica; 2008; 222(5):321-3. PubMed ID: 18617755
[TBL] [Abstract][Full Text] [Related]
37. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
[TBL] [Abstract][Full Text] [Related]
39. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.
Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O
Retina; 2011; 31(7):1261-7. PubMed ID: 21499194
[TBL] [Abstract][Full Text] [Related]
40. Ranibizumab: Phase III clinical trial results.
Rosenfeld PJ; Rich RM; Lalwani GA
Ophthalmol Clin North Am; 2006 Sep; 19(3):361-72. PubMed ID: 16935211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]